Question

The first approved treatment for primary progressive multiple sclerosis, ocrelizumab, targets this antigen. For 10 points each:
[10m] Name this antigen found on the surface of B cells. This antigen is targeted by the first antibody approved for cancer patients, rituximab.
ANSWER: CD20 [accept MS4A1]
[10h] In addition to attracting NK cells in antibody-dependent cellular cytotoxicity, rituximab also induces complement-dependent cytotoxicity. This protein complex binds to antibody-antigen complexes in the classical complement pathway.
ANSWER: C1 [or complement component 1; accept C1q or complement component 1q]
[10e] The suffix “-mab” in rituximab and ocrelizumab refers to them being medicines composed of these antibodies. Fused hybridomas produce these antibodies which target a single epitope.
ANSWER: monoclonal antibodies [or mAb]
<Science - Biology>

Back to bonuses

Summary

2024 ARGOS @ Chicago11/23/2024Y613.33100%33%0%
2024 ARGOS @ Columbia11/23/2024Y33.3333%0%0%
2024 ARGOS @ McMaster11/17/2024Y58.0060%20%0%

Data

BHSU RebirthNortheast by Northwestern1001020
Clown SenpaisNotre Dame001010
BHSU ReFantazioClown Squad1001020
hawk two ofThat Feeling When Knee Surgery Is in Five Days001010
Music to Help You Stop SmokingWashU001010
Who is the Colleen Hoover of the Zulus?The Love Song of J Alfred PrufRock and Roll All Nite (and Party Every Day)001010